NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Encoded Therapeutics

Encoded Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://encoded.com/

Last Round

Series D

Jul 22, 2020

Total Funding Raised

$239.1M

Company Overview

Encoded Therapeutics is a biotechnology company developing precision genetic medicines for severe neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

gene therapyprecision medicineDravet syndromebiotechgenomics discoveryAAV vectorsregulatory DNA elementscomputational biologydrug discoveryclinical trialsbiologics license applicationBLAin silico drug designAI-native biotechgene editing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Encoded Therapeutics Comparables

Compare Encoded Therapeutics with similar companies based on industry and business-model similarity.

Encoded Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stoke Therapeutics, Inc.
84%
Harmony Biosciences Holdings, Inc.
76%
Takeda
70%

Encoded Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJul 22, 2020
Series CJun 26, 2019
SeedApr 18, 2017
AcceleratorJul 30, 2015
AcceleratorOct 15, 2014

Key People

Founding team and executive leadership

Stephanie Tagliatela

Co-Founder and Chief Scientific Officer

Founding Team

Encoded Therapeutics Investors

Notable investors and investment history

Encoded Therapeutics investors
InvestorRounds
SoftBank Investment AdvisersSeries D
Farallon Capital ManagementSeries D
Boxer CapitalSeries C, Series D
GVSeries D
Altitude Life Science VenturesSeries C, Seed
ARCH Venture PartnersSeries C, Seed, Series D
SoftBank GroupSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 6, 2026

    Developing ETX101, a gene therapy for Dravet syndrome, preparing for BLA submission.

  • Jul 22, 2020

    $135M round led by GV

Encoded Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Encoded Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Encoded Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range176
Year Founded2014
Last FundingJul 22, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.